1. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study;Abou-Alfa;Lancet Oncol.,2020
2. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study;Abou-Alfa;Lancet Oncol.,2020
3. The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization;Angerilli;Diagn. (Basel, Switz. ),2021
4. FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice;Angerilli;Pathologica,2023
5. Anon. https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre.